Skip to main content

Table 3 Exposure to different oral OA therapies in the 3 years prior to index date

From: Impact of oral osteoarthritis therapy usage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort

  Knee replacement
Oral OA therapies, % (n) Case (n = 161)a Control (n = 360)a
Acetaminophen
 No exposure 70.2% (113) 75.0% (270)
 Exposure 1–79% 26.7% (43) 22.5% (81)
 Exposure ≥ 80% 3.1% (5) 2.5% (9)
NSAIDs
 No exposure 37.3% (60) 51.4% (185)
 Exposure 1–79% 38.5% (62) 33.3% (120)
 Exposure ≥ 80% 24.2% (39) 15.3% (55)
COX-2 inhibitors
 No exposure 86.3% (139) 91.1% (328)
 Exposure 1–79% 7.5% (12) 4.7% (17)
 Exposure ≥ 80% 6.2% (10) 4.2% (15)
Narcotics
 No exposure 88.8% (143) 89.7% (323)
 Exposure 1–79% 10.0% (16) 7.5% (27)
 Exposure ≥ 80% 1.2% (2) 2.8% (10)
Glucosamine/chondroitin sulfate
 No exposure 45.3% (73) 45.8% (165)
 Exposure 1–79% 23.0% (37) 23.1% (83)
 Exposure ≥ 80% 31.7% (51) 31.1% (112)
  1. Data shown are proportion of patients (%) and number of patients (n)
  2. COX-2 cyclooxygenase-2, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis
  3. aOf the total number of cases (218) and controls (540), 161 cases and 360 controls had complete information for the 3 years prior to index date